OMEGA-3-FATTY ACID SUPPLEMENTATION TO PREVENT PRETERM BIRTH AMONG WOMEN AT RISK

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。早产仍然是沿着非异常婴儿死亡率和发病率的因果途径的一个重要组成部分。在最近完成的每周注射17 α-羟孕酮己酸酯（17 P）的试验中，国家儿童健康和人类发展研究所（NICHD）产妇胎儿医学单位（MFMU）网络发现这些治疗在预防复发性早产方面显着有益。 这项研究的目的是确定除了注射17 P外，欧米茄-3（一种多不饱和脂肪酸营养补充剂）是否能降低高危妇女的早产率。有过早产史且在妊娠21周或之前接受产前护理的妇女有资格参加。妇女每周接受一次注射。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Preterm birth remains an essential component along the causal pathway for non-anomalous infant mortality and morbidity. In a recently completed trial of weekly injections of 17 alpha hydroxyprogesterone caproate (17P), the National Institute of Child Health and Human Development (NICHD) Maternal Fetal Medicine Unit (MFMU) Network found the treatments significantly beneficial in the prevention of recurrent preterm birth. The purpose of this study is to determine whether Omega-3, a polyunsaturated fatty acid nutritional supplement, in addition to injections of 17P decreases the rate of preterm birth in women at risk. Women who have had a previous preterm birth who appear for prenatal care on or before 21 weeks of gestation are eligible. Women will receive weekly injections.